A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

Christophe Massard; Teuvo L.J. Tammela; Egils Vjaters; V. Lietuvietis; Petri Bono; Heidi Penttinen; Pirjo Nykänen; Amir Snapir; Leena Mattila; Karim Fizazi

doi:10.1200/jco.2014.32.4_suppl.115

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

Identifier:nobleid.org/w1/20260515/967EDBC9

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/967EDBC9.svg?ark=w1%2F20260515%2F967EDBC9)](https://nobleid.org/work/w1/20260515/967EDBC9)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

Identifier:nobleid.org/w1/20260515/967EDBC9

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/967EDBC9.svg?ark=w1%2F20260515%2F967EDBC9)](https://nobleid.org/work/w1/20260515/967EDBC9)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work